Marinomed Biotech Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of MARI?
Owner Type	Number of Shares	Ownership Percentage
Private Companies	12,310	0.726%
Institutions	429,321	25.3%
Individual Insiders	525,321	31%
General Public	727,631	42.9%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.5%.

Top Shareholders

Top 17 shareholders own 57.06% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
10%	LLB Invest Kapitalanlagegesellschaft m.b.H.	169,666	€2.5m	8.59%	0.23%
7.87%	Erste Asset Management GmbH	133,350	€2.0m	0%	0.02%
7.36%	Hermann Unger	124,783	€1.9m	0%	no data
7.18%	Eva Prieschl-Grassauer	121,702	€1.8m	0%	no data
7.18%	Andreas Grassauer	121,702	€1.8m	0%	no data
4.64%	Abdulmohsen Al Sheikh	78,567	€1.2m	0%	no data
4.64%	Mohammed Al Sheikh	78,567	€1.2m	0%	no data
3.88%	Matejka & Partner Asset Management GmbH	65,688	€985.3k	0%	2.76%
1.2%	3 Banken-Generali Investment-Gesellschaft m.b.H.	20,400	€306.0k	0%	0.01%
0.87%	Sk VermÖGensverwaltung GmbH	14,765	€221.5k	0%	0.04%
0.73%	Acropora Beteiligungs GmbH	12,310	€184.6k	0%	no data
0.64%	amandea Vermögensverwaltung AG	10,889	€163.3k	0%	0.45%
0.38%	Vogt Asset Management Trust Reg.	6,515	€97.7k	0%	0.06%
0.3%	Sparkasse Oberösterreich Kapitalanlagegesellschaft mbH	5,000	€75.0k	-56.3%	0.01%
0.097%	Fund Development & Advisory AG	1,650	€24.8k	0%	0.03%
0.066%	Gutmann Kapitalanlageaktiengesellschaft	1,120	€16.8k	0%	no data
0.016%	EB Portfoliomanagement GmbH	278	€4.2k	0%	no data

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/30 14:31
End of Day Share Price	2024/12/30 00:00
Earnings	2024/03/31
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Marinomed Biotech AG is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Norbert Kalliwoda	Dr. Kalliwoda Research
Vladimira Urbankova	Erste Group Bank AG
Christian Ehmann	FMR - Frankfurt Main Research AG